The ProVet APC system is a revolutionary device and is arguably the fastest and most transportable platelet concentrator available to the veterinary industry at less than 3 pounds total weight. Some of the system features include the ability to isolate approximately 90 percent of available platelets and growth factors, delivering the highest level of reproducibility with a low 3.5 percent coefficient of variance and a 97 percent reduction in red blood cell numbers.

The proprietary technology found within ProVet APC consistently delivers 6 to 8mls of 7.8 times high concentration of platelet rich plasma and a healing concentrate derived from 54mls of whole blood in the 60ml system.

Mike Eldred, President of Dechra North America stated, “The medical industry has long recognized that harnessing the growth factors found in platelets positively enhances healing results and reduces recovery time in soft tissue injuries. These two products will be great additions to our equine product line and further strengthen our market position in veterinary regenerative medicine.”

“ProVet APC has become the most highly sought-after regenerative system for equine athletes,” said Amy Hassinger, CEO Hassinger Biomedical. “We believe Dechra is specially poised, through their experience in the veterinary sector to meet the growing global demand by veterinarians and their clients for the ProVet APC and BMC Regenerative  Therapy Systems.”

This addition of the Provet APC products to Dechra's equine portfolio will complement our industry leading Orthokine® Vet irap joint therapy and provides veterinarians with a one stop partner for their regenerative medicine needs.

Read more here.

The post Dechra Acquires License For Two Equine Regenerative Therapy Systems appeared first on Horse Racing News | Paulick Report.

Source of original post